These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
297 related articles for article (PubMed ID: 26880382)
1. The PD-1/PD-L1 axis in the pathogenesis of urothelial bladder cancer and evaluating its potential as a therapeutic target. Bardoli AD; Afshar M; Viney R; Foster M; Porfiri E; Zarkar A; Stevenson R; James ND; Bryan RT; Patel P Future Oncol; 2016 Mar; 12(5):595-600. PubMed ID: 26880382 [No Abstract] [Full Text] [Related]
2. Anti-PD-1 and PD-L1 therapy for bladder cancer: what is on the horizon? Sundararajan S; Vogelzang NJ Future Oncol; 2015; 11(16):2299-306. PubMed ID: 26260808 [TBL] [Abstract][Full Text] [Related]
3. PD-1 blockade therapy in renal cell carcinoma: current studies and future promises. Massari F; Santoni M; Ciccarese C; Santini D; Alfieri S; Martignoni G; Brunelli M; Piva F; Berardi R; Montironi R; Porta C; Cascinu S; Tortora G Cancer Treat Rev; 2015 Feb; 41(2):114-21. PubMed ID: 25586601 [TBL] [Abstract][Full Text] [Related]
4. Immune Checkpoint Therapy in Melanoma. Callahan MK Cancer J; 2016; 22(2):73-80. PubMed ID: 27111901 [TBL] [Abstract][Full Text] [Related]
7. Immune Checkpoint Therapy in Renal Cell Carcinoma. Lee CH; Motzer RJ Cancer J; 2016; 22(2):92-5. PubMed ID: 27111903 [TBL] [Abstract][Full Text] [Related]
8. Anti-PD-L1 antibody active in metastatic bladder cancer. Brower V Lancet Oncol; 2015 Jan; 16(1):e11. PubMed ID: 25638546 [No Abstract] [Full Text] [Related]
9. The evolution of checkpoint blockade as a cancer therapy: what's here, what's next? Shin DS; Ribas A Curr Opin Immunol; 2015 Apr; 33():23-35. PubMed ID: 25621841 [TBL] [Abstract][Full Text] [Related]
10. The State of Immune Checkpoint Inhibition in Urothelial Carcinoma: Current Evidence and Future Areas of Exploration. Campbell MT; Siefker-Radtke AO; Gao J Cancer J; 2016; 22(2):96-100. PubMed ID: 27111904 [TBL] [Abstract][Full Text] [Related]
11. Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy. McArthur HL; Page DB Clin Adv Hematol Oncol; 2016 Nov; 14(11):922-933. PubMed ID: 27930644 [TBL] [Abstract][Full Text] [Related]
12. Targeting the PD1/PD-L1 axis in melanoma: biological rationale, clinical challenges and opportunities. Merelli B; Massi D; Cattaneo L; Mandalà M Crit Rev Oncol Hematol; 2014 Jan; 89(1):140-65. PubMed ID: 24029602 [TBL] [Abstract][Full Text] [Related]
13. The science of checkpoint inhibition in kidney cancer. Clin Adv Hematol Oncol; 2016 Apr; 14(4):214-7. PubMed ID: 27166601 [No Abstract] [Full Text] [Related]
14. Checkpoint Inhibition: Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors in Hodgkin Lymphoma. Villasboas JC; Ansell S Cancer J; 2016; 22(1):17-22. PubMed ID: 26841012 [TBL] [Abstract][Full Text] [Related]
15. [Implications of TCGA Network Data on 2nd Generation Immunotherapy Concepts Based on PD-L1 and PD-1 Target Structures]. Peters I; Tezval H; Kramer MW; Wolters M; Grünwald V; Kuczyk MA; Serth J Aktuelle Urol; 2015 Nov; 46(6):481-5. PubMed ID: 26560846 [TBL] [Abstract][Full Text] [Related]
16. Non-Small Cell Lung Cancer, PD-L1, and the Pathologist. Kerr KM; Nicolson MC Arch Pathol Lab Med; 2016 Mar; 140(3):249-54. PubMed ID: 26927720 [TBL] [Abstract][Full Text] [Related]
17. PD-1 blockade attenuates immunosuppressive myeloid cells due to inhibition of CD47/SIRPα axis in HPV negative head and neck squamous cell carcinoma. Yu GT; Bu LL; Huang CF; Zhang WF; Chen WJ; Gutkind JS; Kulkarni AB; Sun ZJ Oncotarget; 2015 Dec; 6(39):42067-80. PubMed ID: 26573233 [TBL] [Abstract][Full Text] [Related]
18. Is PD-L1 Expression a Biomarker of Response? Colwell J Cancer Discov; 2015 Dec; 5(12):1232. PubMed ID: 26516064 [TBL] [Abstract][Full Text] [Related]
19. Association between B7-H1 expression and bladder cancer: a meta-analysis. Wang YU; Liu AN; Zhao SH Genet Mol Res; 2015 Feb; 14(1):1277-86. PubMed ID: 25730066 [TBL] [Abstract][Full Text] [Related]
20. The prognostic significance of PD-L1 in bladder cancer. Huang Y; Zhang SD; McCrudden C; Chan KW; Lin Y; Kwok HF Oncol Rep; 2015 Jun; 33(6):3075-84. PubMed ID: 25963805 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]